Feline Atopic Dermatitis Treatment Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,000	250 Pages	Future Market Insights	June, 2022	FMARI18188395

Best Price Guarantee
Price	from $5,000
Length	250 Pages
Publisher	Future Market Insights
Published Date	June, 2022
SKU	FMARI18188395

Feline Atopic Dermatitis Treatment Market

Feline atopic dermatitis is the inflammation of the skin seen in the cats. Feline atopic dermatitis is often triggered by causative allergens which are either inhaled or through skin contact leading to inflammation of the skin. As per the study carried out by the Canadian Veterinary Journal the conservative prevalence of the feline atopic dermatitis in the cats is around 12.5% whereas the actual prevalence is high as it is very common disorder in cats. The diagnosis of the often starts when itchy skin is observed in the cats. The feline atopic dermatitis treatment often involves the medications which help to decrease the immune response which causes pruritus. Various non-inflammatory drugs are also used in the feline atopic dermatitis treatment. Most often the feline atopic dermatitis is lifelong condition of inflamed skin, it may be seasonal or non-seasonal which leads to frequent visits to veterinarians for feline atopic dermatitis treatment.

Feline Atopic Dermatitis Treatment Market: Drivers and Restraints

High prevalence of atopic dermatitis among the cats irrespective of the region expected to drive the growth of the feline atopic dermatitis treatment market. Around 62.0% of U.S. households have one or more companion animals and it is expected to increase rapidly which in turn expected to drive the growth of the feline atopic dermatitis treatment market. Increasing trend of companion animals in regions such as Asia-Pacific and Latin America further expected to fuel the growth of the feline atopic dermatitis treatment market. Increasing diagnosis and subsequently increasing treatment seeking rate for various diseases in companion animals further expected to drive the growth of the feline atopic dermatitis treatment market. Increasing number of companion animals coupled with increasing number of veterinarians in the developing countries expected to drive the growth of the feline atopic dermatitis treatment market. Whereas, lack of novel treatment which can prevent the reoccurrence of the atopic dermatitis may hamper the growth of the feline atopic dermatitis treatment market.

Feline Atopic Dermatitis Treatment Market: Segmentation

The global feline atopic dermatitis treatment market is segmented on the basis of the drug class, route of administration, distribution channel and region

By drug class, the global feline atopic dermatitis treatment market is segmented as:

Corticosteroids
Antihistamines
Antibiotics

By route of administration, the global feline atopic dermatitis treatment market is segmented as:

Oral
Topical
Injectable

By distribution channel, the global feline atopic dermatitis treatment market is segmented as:

Veterinary Pharmacies
Retail Pharmacies
Online Pharmacies

Feline Atopic Dermatitis Treatment Market: Overview

The global feline atopic dermatitis treatment market is expected to experience significant growth due to increasing prevalence of the feline atopic dermatitis. By drug class, corticosteroids is expected to dominate the global feline atopic dermatitis treatment market by revenue due to higher efficacy as compared to other drug classes. By route of administration, feline atopic dermatitis treatment market is expected to be dominated by topical segment due to higher compliance. By distribution channel, feline atopic dermatitis treatment market is expected to be dominated by veterinary pharmacies due to higher footfall.

Feline Atopic Dermatitis Treatment Market: Regional Outlook

North America expected to dominate the global feline atopic dermatitis treatment market due to higher number of companion animals in the region. Europe feline atopic dermatitis treatment market due to increasing number of companion animals as well as higher treatment seeking rate as compared to other developing regions. Asia-Pacific is emerging feline atopic dermatitis treatment market due to rapidly increasing companion animal ownership and emerging countries such as India and China. Latin America is expected to experience gradual growth in the feline atopic dermatitis treatment market due to increasing product availability in the region. Middle East & Africa feline atopic dermatitis treatment market is expected to be least lucrative market due to least adoption of feline atopic dermatitis treatment.

Feline Atopic Dermatitis Treatment Market: Key Players

The key market players operating in the feline atopic dermatitis treatment market are: Bausch Health Companies Inc., Bayer AG, Pfizer Inc., Novartis AG, Eli Lily Company, Sanofi, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Indication
Value Chain

Regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain)
Eastern Europe (Poland, Russia)
Asia-Pacific excluding Japan (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current, and projected market size in terms of volume and value
Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

1. Executive Summary: 1.1. Global Market Outlook; 1.2. Demand-side Trends; 1.3. Supply-side Trends; 1.4. Technology Roadmap Analysis; 1.5. Analysis and Recommendations
2. Market Overview: 2.1. Market Coverage / Taxonomy; 2.2. Market Definition / Scope / Limitations
3. Market Background: 3.1. Market Dynamics; 3.1.1. Drivers; 3.1.2. Restraints; 3.1.3. Opportunity; 3.1.4. Trends; 3.2. Scenario Forecast; 3.2.1. Demand in Optimistic Scenario; 3.2.2. Demand in Likely Scenario; 3.2.3. Demand in Conservative Scenario; 3.3. Opportunity Map Analysis; 3.4. Investment Feasibility Matrix; 3.5. Value Chain Analysis; 3.5.1. Profit Margin Analysis; 3.5.2. Service Providers; 3.6. PESTLE and Porter’s Analysis; 3.7. Regulatory Landscape; 3.7.1. By Key Regions; 3.7.2. By Key Countries; 3.8. Regional Parent Market Outlook
4. Global Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast, 2022-2032: 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021; 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032; 4.2.1. Y-o-Y Growth Trend Analysis; 4.2.2. Absolute $ Opportunity Analysis
5. Global Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class: 5.1. Introduction / Key Findings; 5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2021; 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032; 5.3.1. Corticosteroids; 5.3.2. Antihistamines; 5.3.3. Antibiotics; 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021; 5.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032
6. Global Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration: 6.1. Introduction / Key Findings; 6.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2017-2021; 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032; 6.3.1. Oral; 6.3.2. Topical; 6.3.3. Injectable; 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021; 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032
7. Global Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel: 7.1. Introduction / Key Findings; 7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021; 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032; 7.3.1. Veterinary Pharmacies; 7.3.2. Retail Pharmacies; 7.3.3. Online Pharmacies; 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021; 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032
8. Global Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Region: 8.1. Introduction; 8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021; 8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032; 8.3.1. North America; 8.3.2. Latin America; 8.3.3. Europe; 8.3.4. East Asia; 8.3.5. South Asia & Pacific; 8.3.6. MEA; 8.4. Market Attractiveness Analysis By Region
9. North America Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 9.2.1. By Country; 9.2.1.1. U.S.; 9.2.1.2. Canada; 9.2.2. By Drug Class; 9.2.3. By Route of Administration; 9.2.4. By Distribution Channel; 9.3. Market Attractiveness Analysis; 9.3.1. By Country; 9.3.2. By Drug Class; 9.3.3. By Route of Administration; 9.3.4. By Distribution Channel; 9.4. Key Takeaways
10. Latin America Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 10.2.1. By Country; 10.2.1.1. Mexico; 10.2.1.2. Brazil; 10.2.1.3. Rest of Latin America; 10.2.2. By Drug Class; 10.2.3. By Route of Administration; 10.2.4. By Distribution Channel; 10.3. Market Attractiveness Analysis; 10.3.1. By Country; 10.3.2. By Drug Class; 10.3.3. By Route of Administration; 10.3.4. By Distribution Channel; 10.4. Key Takeaways
11. Europe Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 11.2.1. By Country; 11.2.1.1. Germany; 11.2.1.2. Italy; 11.2.1.3. France; 11.2.1.4. U.K.; 11.2.1.5. Spain; 11.2.1.6. BENELUX; 11.2.1.7. Russia; 11.2.1.8. Rest of Europe; 11.2.2. By Drug Class; 11.2.3. By Route of Administration; 11.2.4. By Distribution Channel; 11.3. Market Attractiveness Analysis; 11.3.1. By Country; 11.3.2. By Drug Class; 11.3.3. By Route of Administration; 11.3.4. By Distribution Channel; 11.4. Key Takeaways
12. East Asia Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 12.2.1. By Country; 12.2.1.1. China; 12.2.1.2. Japan; 12.2.1.3. South Korea; 12.2.2. By Drug Class; 12.2.3. By Route of Administration; 12.2.4. By Distribution Channel; 12.3. Market Attractiveness Analysis; 12.3.1. By Country; 12.3.2. By Drug Class; 12.3.3. By Route of Administration; 12.3.4. By Distribution Channel; 12.4. Key Takeaways
13. South Asia & Pacific Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 13.2.1. By Country; 13.2.1.1. India; 13.2.1.2. ASEAN; 13.2.1.3. Australia and New Zealand; 13.2.1.4. Rest of South Asia & Pacific; 13.2.2. By Drug Class; 13.2.3. By Route of Administration; 13.2.4. By Distribution Channel; 13.3. Market Attractiveness Analysis; 13.3.1. By Country; 13.3.2. By Drug Class; 13.3.3. By Route of Administration; 13.3.4. By Distribution Channel; 13.4. Key Takeaways
14. MEA Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 14.2.1. By Country; 14.2.1.1. GCC Countries; 14.2.1.2. Turkey; 14.2.1.3. South Africa; 14.2.1.4. Rest of MEA; 14.2.2. By Drug Class; 14.2.3. By Route of Administration; 14.2.4. By Distribution Channel; 14.3. Market Attractiveness Analysis; 14.3.1. By Country; 14.3.2. By Drug Class; 14.3.3. By Route of Administration; 14.3.4. By Distribution Channel; 14.4. Key Takeaways
15. Key Countries Feline Atopic Dermatitis Treatment Market Analysis: 15.1. U.S.; 15.1.1. Pricing Analysis; 15.1.2. Market Share Analysis, 2021; 15.1.2.1. By Drug Class; 15.1.2.2. By Route of Administration; 15.1.2.3. By Distribution Channel; 15.2. Canada; 15.2.1. Pricing Analysis; 15.2.2. Market Share Analysis, 2021; 15.2.2.1. By Drug Class; 15.2.2.2. By Route of Administration; 15.2.2.3. By Distribution Channel; 15.3. Mexico; 15.3.1. Pricing Analysis; 15.3.2. Market Share Analysis, 2021; 15.3.2.1. By Drug Class; 15.3.2.2. By Route of Administration; 15.3.2.3. By Distribution Channel; 15.4. Brazil; 15.4.1. Pricing Analysis; 15.4.2. Market Share Analysis, 2021; 15.4.2.1. By Drug Class; 15.4.2.2. By Route of Administration; 15.4.2.3. By Distribution Channel; 15.5. Germany; 15.5.1. Pricing Analysis; 15.5.2. Market Share Analysis, 2021; 15.5.2.1. By Drug Class; 15.5.2.2. By Route of Administration; 15.5.2.3. By Distribution Channel; 15.6. Italy; 15.6.1. Pricing Analysis; 15.6.2. Market Share Analysis, 2021; 15.6.2.1. By Drug Class; 15.6.2.2. By Route of Administration; 15.6.2.3. By Distribution Channel; 15.7. France; 15.7.1. Pricing Analysis; 15.7.2. Market Share Analysis, 2021; 15.7.2.1. By Drug Class; 15.7.2.2. By Route of Administration; 15.7.2.3. By Distribution Channel; 15.8. U.K.; 15.8.1. Pricing Analysis; 15.8.2. Market Share Analysis, 2021; 15.8.2.1. By Drug Class; 15.8.2.2. By Route of Administration; 15.8.2.3. By Distribution Channel; 15.9. Spain; 15.9.1. Pricing Analysis; 15.9.2. Market Share Analysis, 2021; 15.9.2.1. By Drug Class; 15.9.2.2. By Route of Administration; 15.9.2.3. By Distribution Channel; 15.10. BENELUX; 15.10.1. Pricing Analysis; 15.10.2. Market Share Analysis, 2021; 15.10.2.1. By Drug Class; 15.10.2.2. By Route of Administration; 15.10.2.3. By Distribution Channel; 15.11. Russia; 15.11.1. Pricing Analysis; 15.11.2. Market Share Analysis, 2021; 15.11.2.1. By Drug Class; 15.11.2.2. By Route of Administration; 15.11.2.3. By Distribution Channel; 15.12. China; 15.12.1. Pricing Analysis; 15.12.2. Market Share Analysis, 2021; 15.12.2.1. By Drug Class; 15.12.2.2. By Route of Administration; 15.12.2.3. By Distribution Channel; 15.13. Japan; 15.13.1. Pricing Analysis; 15.13.2. Market Share Analysis, 2021; 15.13.2.1. By Drug Class; 15.13.2.2. By Route of Administration; 15.13.2.3. By Distribution Channel; 15.14. South Korea; 15.14.1. Pricing Analysis; 15.14.2. Market Share Analysis, 2021; 15.14.2.1. By Drug Class; 15.14.2.2. By Route of Administration; 15.14.2.3. By Distribution Channel; 15.15. India; 15.15.1. Pricing Analysis; 15.15.2. Market Share Analysis, 2021; 15.15.2.1. By Drug Class; 15.15.2.2. By Route of Administration; 15.15.2.3. By Distribution Channel; 15.16. ASEAN; 15.16.1. Pricing Analysis; 15.16.2. Market Share Analysis, 2021; 15.16.2.1. By Drug Class; 15.16.2.2. By Route of Administration; 15.16.2.3. By Distribution Channel; 15.17. Australia and New Zealand; 15.17.1. Pricing Analysis; 15.17.2. Market Share Analysis, 2021; 15.17.2.1. By Drug Class; 15.17.2.2. By Route of Administration; 15.17.2.3. By Distribution Channel; 15.18. GCC Countries; 15.18.1. Pricing Analysis; 15.18.2. Market Share Analysis, 2021; 15.18.2.1. By Drug Class; 15.18.2.2. By Route of Administration; 15.18.2.3. By Distribution Channel; 15.19. Turkey; 15.19.1. Pricing Analysis; 15.19.2. Market Share Analysis, 2021; 15.19.2.1. By Drug Class; 15.19.2.2. By Route of Administration; 15.19.2.3. By Distribution Channel; 15.20. South Africa; 15.20.1. Pricing Analysis; 15.20.2. Market Share Analysis, 2021; 15.20.2.1. By Drug Class; 15.20.2.2. By Route of Administration; 15.20.2.3. By Distribution Channel
16. Market Structure Analysis: 16.1. Competition Dashboard; 16.2. Competition Benchmarking; 16.3. Market Share Analysis of Top Players; 16.3.1. By Regional; 16.3.2. By Drug Class; 16.3.3. By Route of Administration; 16.3.4. By Distribution Channel
17. Competition Analysis: 17.1. Competition Deep Dive; 17.1.1. Bausch Health Companies Inc.; 17.1.1.1. Overview; 17.1.1.2. Product Portfolio; 17.1.1.3. Profitability by Market Segments; 17.1.1.4. Sales Footprint; 17.1.1.5. Strategy Overview; 17.1.1.5.1. Marketing Strategy; 17.1.1.5.2. Product Strategy; 17.1.1.5.3. Channel Strategy; 17.1.2. Bayer AG; 17.1.2.1. Overview; 17.1.2.2. Product Portfolio; 17.1.2.3. Profitability by Market Segments; 17.1.2.4. Sales Footprint; 17.1.2.5. Strategy Overview; 17.1.2.5.1. Marketing Strategy; 17.1.2.5.2. Product Strategy; 17.1.2.5.3. Channel Strategy; 17.1.3. Pfizer Inc.; 17.1.3.1. Overview; 17.1.3.2. Product Portfolio; 17.1.3.3. Profitability by Market Segments; 17.1.3.4. Sales Footprint; 17.1.3.5. Strategy Overview; 17.1.3.5.1. Marketing Strategy; 17.1.3.5.2. Product Strategy; 17.1.3.5.3. Channel Strategy; 17.1.4. Novartis AG; 17.1.4.1. Overview; 17.1.4.2. Product Portfolio; 17.1.4.3. Profitability by Market Segments; 17.1.4.4. Sales Footprint; 17.1.4.5. Strategy Overview; 17.1.4.5.1. Marketing Strategy; 17.1.4.5.2. Product Strategy; 17.1.4.5.3. Channel Strategy; 17.1.5. Eli Lily Company; 17.1.5.1. Overview; 17.1.5.2. Product Portfolio; 17.1.5.3. Profitability by Market Segments; 17.1.5.4. Sales Footprint; 17.1.5.5. Strategy Overview; 17.1.5.5.1. Marketing Strategy; 17.1.5.5.2. Product Strategy; 17.1.5.5.3. Channel Strategy; 17.1.6. Sanofi; 17.1.6.1. Overview; 17.1.6.2. Product Portfolio; 17.1.6.3. Profitability by Market Segments; 17.1.6.4. Sales Footprint; 17.1.6.5. Strategy Overview; 17.1.6.5.1. Marketing Strategy; 17.1.6.5.2. Product Strategy; 17.1.6.5.3. Channel Strategy; 17.1.7. Bristol-Myers Squibb Company; 17.1.7.1. Overview; 17.1.7.2. Product Portfolio; 17.1.7.3. Profitability by Market Segments; 17.1.7.4. Sales Footprint; 17.1.7.5. Strategy Overview; 17.1.7.5.1. Marketing Strategy; 17.1.7.5.2. Product Strategy; 17.1.7.5.3. Channel Strategy; 17.1.8. Boehringer Ingelheim International GmbH; 17.1.8.1. Overview; 17.1.8.2. Product Portfolio; 17.1.8.3. Profitability by Market Segments; 17.1.8.4. Sales Footprint; 17.1.8.5. Strategy Overview; 17.1.8.5.1. Marketing Strategy; 17.1.8.5.2. Product Strategy; 17.1.8.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology